Galectin Therapeutics Inc. (GALT)

[JERZYATP1]

Fair enough. In any event the quality of executive personnel is a major factor, and on that we apparently agree, altho in your case
in several instances you've tilted negative toward Traber/Czirr, but
in my case I elected to invest in GALT precisely because of a positive view of them. At the time of my initial investment I was quite aware of Traber's personae (incl. trailer park type) but perceived an underlying intelligence. Fortunately Czirr is simply
seriously straightforward (plus smart). My investment decision also
included consideration of a scientific connection (Harvard) and relatively good financial transparency. In contrast a rival company
working on Galectin inhibition (LaJolla Pharma (LJPC)) didn't
measure up on those criteria, so I avoided it. Subsequently the FDA
rejected LJPC Galectin inhibitor preparation quality, thus LJPC has
suspended work on fibrosis. Meanwhile, GALT passed muster for quality.
Incidentally, while I have no personal knowledge of the occasional
writer Biotech2010, I find his views rather classy, and we are lucky
to have his input along the way.